Sentences with phrase «cell lung cancer»

Further analysis showed some of the activated genes were enriched in small cell lung cancer and other cancer - promoting pathways.

The trial in small - cell lung cancer showed promise.

Some types of lung cancer — for example, small cell lung cancer — are often diagnosed after the cancer has already spread.

For patients with non-small cell lung cancer with brain metastases, treatment with whole brain radiotherapy may not offer much benefit.

42) Garnis C, Lockwood WW, Vucic E, Ge Y, Girard L, Minna JD, Gazdar AF, Lam S, MacAulay C, Lam WL (2006) High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH.

The clinical activity of durvalumab plus tremelimumab in non-small cell lung cancer patients appears to be greater than either agent alone, as reported in prior studies.

In September oncologists reported they sequenced deadly squamous cell lung cancer in 178 patients.

LKB1 Inactivation Dictates Therapeutic Response of Nonsmall Cell Lung Cancer to the Metabolism Drug Phenformin

«Cause of chemoresistance in small cell lung cancer discovered.»

In this study, the researchers focused on a type of non-small cell lung cancer called lung adenocarcinoma, which accounts for about 40 percent of lung cancers.

The final survival results from the PARAMOUNT study in nonsquamous non — small - cell lung cancer confirmed that continuation maintenance therapy with pemetrexed (Alimta) improves survival compared with placebo.

Novel hybrid phenotype revealed in Small Cell Lung Cancer by a transcription factor network model that can explain tumor heterogeneity.

Li RJ, Zhao LJ, Zhan ZL, Lu X, Gong LL, Wang P. [Significance of expression of chemokine receptor and matrix metalloproteinase in small cell lung cancer].

The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.

Dr. Weiss» study of pembrolizumab was presented during a session on small cell lung cancer when the theme of the conference was Science Drives Lung Cancer Advances.

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.

«Treatment - resistant advanced non-small cell lung cancer responds to rociletinib.»

Tan and colleagues put the technique to use to recommend drugs that could turn off the kinases that non-small cell lung cancer uses to create resistance existing treatments.

Non-small cell lung cancer nanoparticles pass the next stage of development in preclinical tests.

Resistance to DNA - damaging treatment in non-small cell lung cancer tumor - initiating cells involves reduced DNA - PK / ATM activation and diminished cell cycle arrest.

Short Research Communication The Factors Reducing Relative Dose Intensity of Cisplatin and Vinorelbine as Adjuvant Chemotherapy in Patients with Non-Small Cell Lung Cancer Ryo Inose, Katsuyuki Takahashi, Naruo Yoshimura, Tomoya Kawaguchi, Mitsutaka Takada, Katsuya Nagayama Oncomedicine 2018; 3: 9 - 14.

Research Paper Serum VEGF levels in the early diagnosis and severity assessment of non-small cell lung cancer Yanzhen Lai, Xueping Wang, Tao Zeng, Shan Xing, Shuqin Dai, Junye Wang, Shulin Chen, Xiaohui Li, Ying Xie, Yuanying Zhu, Wanli Liu J. Cancer 2018; 9 (9): 1538 - 1547.

Saturday, Oct. 21, 9:15 - 9:30 a.m., Room 220B, South Building Platform Presentation: Epigenetic modifications of innate immunity genes impact early - stage non-small cell lung cancer survival: An integrative analysis of epigenome and transcriptome in Caucasian population R. Zhang, Harvard T.H. Chan School of Public Health, et al

Neutrophil - to - Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor

The FDA approved two anti-PD-1 antibodies (nivolumab / Bristol - Myers Squibb and pembrolizumab / Merck & Co.) for metastatic melanoma in 2014, and it extended approval to metastatic squamous non-small cell lung cancer earlier this year.

Scientists from the Cancer Research UK Manchester Institute, based at The University of Manchester and part of the Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug — known as AZD3965 — on small cell lung cancer cells.

More information: Maryna Perepelyuk et al, Evaluation of MUC1 - Aptamer Functionalized Hybrid Nanoparticles for Targeted Delivery of miRNA - 29b to Nonsmall Cell Lung Cancer, Molecular Pharmaceutics (2018).

Lung cancer is the leading cause of cancer - related deaths in the world, and non-small cell lung cancer accounts for > 75 % of all lung cancer cases.

Gerard's lab also sees PD - L1 upregulation by MYC, but intriguingly, how this happens varies depending on cancer type: when MYC is switched on in pancreatic cancer models, PD - L1 is upregulated on the tumour cells themselves, whereas in a non-small cell lung cancer model, it is switched on solely in the macrophages that flood the tumour, despite MYC being activated only in the tumour cells.

«We'd like to extend this further to examine for driver genes in other types of lung cancer, such as squamous cell lung cancer.»

«If 10 years ago you were talking about defining a five - year survival rate for metastatic non-small cell lung cancer patients, someone would laugh in your face.

This drug has already staked its claim in the world of next - gen «checkpoint inhibitor» cancer treatments by besting rival Bristol - Myers Squibb's competing treatment Opdivo in advanced non-small cell lung cancer (NSCLC).

The company has been trying to win FDA approval for Opdivo to be used as a first option treatment for non-small cell lung cancer (NSCLC).

The PD - 1 checkpoint inhibitor Keytruda hit its goals in a new trial in previously untreated non-small cell lung cancer patients, beating chemo at staving off cancer progression and extending patients» lives.

Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly - diagnosed patients with advanced non-small cell lung cancer in a highly - anticipated study that appears to cement the company's lead in the most lucrative oncology market.

NEW YORK / CHICAGO Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly - diagnosed patients with advanced non-small cell lung cancer in a closely - watched study, cementing its lead position over Bristol - Myers Squibb Co and others in the most lucrative oncology market.

April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly - diagnosed patients with advanced non-small cell lung cancer in a highly - anticipated study that appears to cement the company's lead in the most lucrative oncology market.

They'll also jointly market Pfizer's drug Xalkori, which is approved in more than 75 countries for treating non-small cell lung cancer in patients with a certain genetic mutation.

Merck KGaA has released data showing some effectiveness in patients with ovarian cancer and non-small cell lung cancer, and plans more disclosures at medical conferences next year.

Merck already has an FDA approved immunotherapy drug with KEYTRUDA, a treatment for non-small cell lung cancer.

Non — small cell lung cancer may involve genetic aberrations that can be used to direct therapy.